Bayer AG
MIL:1BAYN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Bayer AG (1BAYN) under the Base Case is 47.06 EUR per share.
Compared with the current market price of 53.12 EUR, the stock appears
Overvalued by 11% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Bayer Does
Bayer AG is a life sciences company that makes medicines and crop protection products. In human health, it sells prescription drugs and consumer health products used for areas like heart disease, women’s health, eye care, and pain relief. In agriculture, it sells seeds, traits, herbicides, fungicides, and digital farming tools that help farmers protect crops and improve yields.
- Headquarters
- Germany DE
- Employees
- 88 078
- IPO date
- Nov 28, 1997
Bayer has no economic moat
Patent protection gives Bayer an advantage in some medicines, but it does not prevent cheaper copies from taking business once that protection ends. Competition from generic medicines and crop chemicals limits Bayer’s ability to keep charging higher prices across its businesses.
Read the full moat analysisBalance Sheet
Recent Events
Latest Earnings Call
After nine-month momentum, Bayer upgraded several 2026 outlooks, with Pharma leading performance as management kept litigation resolution and faster innovation in focus.
Open the earnings call- Stock, day of the call
- +3.6%
Past 12 months
Continue 1BAYN Research
Decided on Bayer? Get an email when 1BAYN reaches the price you’d buy at. Free with an account.
Other Bayer listings
What is the Intrinsic Value of one 1BAYN stock?
The intrinsic value for
Bayer AG (1BAYN) under the Base Case is 47.06 EUR.
Is 1BAYN stock undervalued or overvalued?
Compared with the current market price of 53.12 EUR, the stock appears Overvalued by 11% .